Athelas Therapeutics

Athelas Therapeutics was a biotechnology company focused on developing small molecule modulators of CRISPR-Cas9 genome editing systems. Founded by Dr. Amit Choudhary of the Broad Institute and Harvard Medical School, the company aimed to provide precise chemical control over the timing and duration of CRISPR activity to improve safety and efficacy in therapeutic applications. By identifying small molecules that could either inhibit or enhance Cas9 function, Athelas sought to enable transient editing and reduce off-target effects, addressing a major hurdle in the clinical translation of gene editing. The company operated primarily in the seed stage and focused on drugging the CRISPR machinery to create more controllable genetic medicines.